Evidence Review
Protein Quality
Farinon et al. (2020) published a comprehensive review of hemp seed nutritional quality in Nutrients [2]. The authors evaluated hemp seed protein fractions, finding that edestin (70–80% of hemp protein) and albumin (20–30%) together provide a complete essential amino acid profile. The limiting amino acids in hemp protein are lysine and threonine, present in sufficient but not surplus amounts. The biological value of hemp protein is estimated at 87, close to eggs (100) and well above most other plant proteins (legumes typically score 55–70).
The review also characterized hemp seeds' fiber composition (10–15% of whole seeds, primarily insoluble) and mineral content, noting significant levels of phosphorus (~1,650 mg/100g), magnesium (~700 mg/100g), iron (~14 mg/100g), and zinc (~7 mg/100g). The combination of complete protein, favorable fatty acid profile, and mineral density makes hemp seed nutritionally competitive with any plant food.
Cardiovascular Mechanisms
Kaçar et al. (2025) reviewed hempseed's cardiovascular evidence and mechanisms in Frontiers in Nutrition [3]. The review synthesized animal and human data on lipid profiles, blood pressure, oxidative stress, and vascular function. Key points from this analysis:
- Hempseed oil supplementation in multiple animal models consistently reduced total cholesterol, LDL, and triglycerides while maintaining or raising HDL
- The arginine content of hemp protein supports endothelial NO synthesis; arginine-derived NO is a primary vasodilator mechanism
- Gamma-tocopherol present in hemp seed oil suppresses reactive nitrogen species and peroxynitrite in arterial tissue — a mechanism not shared by the alpha-tocopherol in most other vitamin E sources
- The 3:1 LA:ALA ratio is specifically noted as superior to other common seed oils for modulating the omega-6:omega-3 ratio in tissues over time
The authors note that most human clinical evidence on cardiovascular effects is indirect or derived from short-term trials, and call for longer-term RCTs in humans.
Blood Pressure — ACE Inhibition
Girgih et al. (2014) investigated hemp seed meal protein hydrolysates (peptides produced by enzyme digestion of hemp protein, mimicking intestinal digestion) in spontaneously hypertensive rats [4]. The hydrolysates inhibited ACE activity in vitro, with IC50 values comparable to some pharmaceutical ACE inhibitors. In spontaneously hypertensive rats, oral administration significantly reduced systolic blood pressure within hours, with effects persisting for 8 hours after a single dose.
The ACE-inhibitory peptides were characterized by mass spectrometry — specific sequences within hemp protein's edestin fraction appear responsible for the activity. This is a well-established mechanism for food-derived antihypertensive peptides (similar peptides are found in milk casein and soy protein), but direct evidence in humans with hemp-specific peptides is lacking at this time.
Skin Health — Atopic Dermatitis RCT
Callaway et al. (2005) conducted a randomized double-blind crossover trial in 20 patients with atopic dermatitis comparing 2 tablespoons/day of hempseed oil versus olive oil for 8 weeks each, separated by a 4-week washout [5]. Primary outcomes included plasma fatty acid profiles and skin measurements.
Results: Hempseed oil significantly increased plasma LA, ALA, and GLA compared to baseline and versus olive oil (p<0.05 for all). Patients on hempseed oil reported significantly lower scores for dryness, itching, and roughness on validated questionnaires. Transepidermal water loss — an objective measure of skin barrier function — was significantly lower during the hempseed oil period, indicating improved barrier integrity.
The mechanism proposed by the authors centers on dietary GLA: unlike linoleic acid, GLA is not efficiently synthesized by many people (the delta-6 desaturase enzyme is often slow or inhibited by nutrient deficiencies, stress, and aging), so dietary GLA bypasses this bottleneck and provides direct anti-inflammatory substrate. This trial is the strongest human evidence specifically for hemp seed oil and is notable for its crossover design (each patient served as their own control, reducing inter-individual variability).
Limitation: Small sample size (n=20); self-reported symptom outcomes are subject to placebo effects.
Anti-inflammatory Metabolic Effects
Ben Necib et al. (2022) compared hemp seed to linseed (flaxseed) in obese mice fed a high-fat, high-sucrose diet, with dietary fat partially replaced by either hemp seed or linseed [6]. Hemp seed supplementation significantly reduced markers of intestinal permeability (plasma LPS-binding protein), lowered PAI-1 (plasminogen activator inhibitor-1, a clotting risk marker elevated in metabolic syndrome), and modulated the endocannabinoidome — the system of endogenous lipid mediators related to appetite, inflammation, and gut function. Hemp seed increased anti-inflammatory endocannabinoid-related compounds derived from omega-3 fatty acids. Linseed produced different effects, demonstrating that equivalent omega-3 content from different whole-food sources produces distinct metabolic outcomes.
This study highlights hemp seed's potential for addressing metabolic syndrome and intestinal inflammation, though effects were observed in an animal obesity model and require human validation.
Overall Evidence Assessment
For protein quality and completeness: strong evidence from nutritional chemistry and digestibility studies — this is well-established fact rather than an area of controversy. Grade: A.
For cardiovascular benefit (lipid profiles, blood pressure): mechanistic evidence is well-characterized; animal data is robust; human clinical trials are limited to short-term or indirect measures. Grade: B (strong mechanistic foundation, pending large human RCTs).
For skin health (atopic dermatitis): supported by a small but well-designed crossover RCT with objective outcome measures and a plausible GLA mechanism. Grade: B (small sample size limits confidence; additional trials needed).
For anti-inflammatory metabolic effects: primarily preclinical at this stage. Grade: C (promising but not yet human-validated).